NCT02607293View on ClinicalTrials.gov

A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation

CompletedOBSERVATIONAL
Enrollment

1,064

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

March 16, 2017

Study Completion Date

June 28, 2017

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Gonal-f®

Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.

DRUG

Long GnRH agonist

As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.

DRUG

GnRH antagonist

As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.

Trial Locations (1)

Unknown

Merck KGaA Communication Center, Darmstadt

All Listed Sponsors
collaborator

Merck Serono Co., Ltd., China

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT02607293 - A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation | Biotech Hunter | Biotech Hunter